Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 in treatment-resistant depression (TARGET)
NCT04971291Phase 2Unknown
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Apr 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dextromethorphan + bupropion in major depressive disorder (MDD) (2 arms), sponsored by Axsome Therapeutics, Inc. Primary endpoint: Montgomery-Åsberg Depression Rating Scale Total Score at 6 weeks. Status: unknown.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04971291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971291.